John P. Lenihan, Jr., MD      As presented under the auspices of the AAGL 33rd Annual Meeting, November 2004

Feasibility of Performing Nonsurgical Radiofrequency Energy Tissue Micro-Remodeling
 in Women with Stress Urinary Incontinence Using Oral and Local Anesthesia
by John P. Lenihan, MD

 

Curriculum Vitae:

John P. Lenihan, Jr., MD
Tacoma Women's Specialists (TWS)
314 Martin Luther King Jr. Way, Suite 104,
Tacoma, WA 98405
Tele: 253-272-5572 Fax: 253-272-5669

e-mail: john.lenihan@obgyn.net 
website: http://www.tacomaobgyn.com

Education

  • 1966-1970: USAF Academy, Colorado ( B.S. Degree )
  • 1970-1973: Baylor College of Medicine, Houston, TX ( MD)

Postgraduate training

  • 1973: Flight Surgeon, USAF School of Aerospace Medicine, Brooks AFB, San Antonio, TX
  • 1974: Malcolm Grow USAF Med.Center, Washington D.C. (Rotating Internship)
  • 1975-1977: Madigan Army Medical Center, Tacoma, WA (OB-GYN Residency)

Board certification

  • 1980 American Board of Obstetrics and Gynecology

Employment

  • 2000 Tacoma Women’s Specialists, PS, Tacoma WA
  • 1999 Private Practice: OB-GYN, Clinical Research
  • 1995 - 1998 Assoc. Women's Health Specialists, Tacoma WA
  • 1991-1994 Private Practice, OB-GYN-INFERTILITY, Tacoma WA
  • 1982-1990 Dept OB-GYN, (Dept. Chairman),Western Clinic Tacoma, WA
  • 1983-1985 Acting Director, PugetSound Regional Perinatal Service, MultiCare Medical Center, Tacoma, WA
  • 1979-1982 Chief, Dept OB-GYN, USAF Hospital, RAF Lakenheath, United Kingdom
  • 1978-1979 Chief, Dept. OB-GYN, USAF Hospital, Misawa, Japan

Military experience

  • 1970-1982 Active Duty, USAF, Lt. Col. (OB-GYN)
  • 1999-present USAF Reserve, Lt. Col. (Flight Surgeon)
  • 2001-present Chief of Aerospace Medicine: 446th AMDS, McChord AFB WA (USAFR)

Teaching

  • 1989-present: Asst Clinical Professor, Dept.OB-GYN, Univ.of Washington School of Medicine
  • 1982-1993: Clinical Faculty, OB-GYN, Tacoma Family Medicine Residency Program, Tacoma, WA
  • 1983-1993 Education Coordinator, OB-GYN, Multicare Medical Center, Tacoma, WA
  • 1984-1991 Board Member, College of Medical Education Pierce County Medical Society

Awards

  • ACOG CME Recognition Award, 1985, 1988, 1992, 1994
  • Physicians Recognition Award. AMA, 1981, 1985, 1989
  • Outstanding Instructor (OB-GYN), Tacoma Family Medicine, 1984,1987
  • Senior Member: AIUM (American Institute of Ultrasound in Medicine) March 2002

Committee appointments

  • Board: Associated Women's Health Specialists LLC 1995-1998
  • Board: Northwest Physicians Network (I.P.A.) 1997-99, President 2000 - 2002
  • Joint Credential Committee, Tacoma General Hospital 1995 -1997
  • Medical Staff President, Tacoma General Hospital 1994
  • OB-GYN Committee, Tacoma General Hospital (1983-1994)
  • Chairman: (1991-1992)
  • OB-GYN Quality Assurance Committee, Tacoma General Hospital
  • (1986-1993), Chairman: 1989-1990
  • LASER and New Technology Committee, MultiCare Medical Center Chairman 1986-1996
  • Western Clinic Executive Committee, 1984-86, 1987-89

Societies

  • American College of OB-GYN - Fellow
  • American Medical Association
  • Washington State Medical Association
  • Washington State Obstetrical Association
  • American Society of Reproductive Medicine
  • Pierce County Medical Society
  • American Association of Gynecologic Laparoscopists
  • International Society for Minimally Invasive Therapy
  • American Institute of Ultrasound in Medicine

License

  • Washington State
  • Texas

Publications

  1. Significance of Neutrophils in Amniotic Fluid, Weis, Lenihan and Larsen, OB-GYN, 47:143, 1976.
  2. Rape, A Simplified Approach To The Management of Sexual Assault, and a review of 57 Consecutive Cases, Lenihan and Brown, presented at District VIII ACOG, WA D.C., Oct 1978.
  3. Association of Premature Rupture of the Membranes with Ante- Partum Last Trimester Pelvic Exams, Lenihan, OB-GYN, Vol. 83, No. 1., Jan 1984.
  4. Low dose unopposed Estrogens: Preliminary Findings on the Frequency and Duration of Vaginal Bleeding in Postmenopausal Women receiving Esterified Estrogens over a Two Year Period: Trabal, Lenihan, et al.., Menopause 1997;4, 130-8.
  5. An Open-Label, Multicenter, Noncomparative Safety and Efficacy Study of Mircette, a Low Dose Estrogen-Progestin Oral Contraceptive. The Mircette Study Group, AmJOB-GYN,179,No1,7/98
  6. Efficacy & Safety of Low, Standard and High Dosages of an Estradiol Transdermal System (ESCLIM@) Compared with Placebo on Vasomotor Symptoms in Highly Symptomatic Menopausal Patients., Utian et al., AmJOB-GYN, 9/99.
  7. Low Dose Esterified Estrogen Therapy, Effects on Bone, Plasma Estradiol Concentrations, Endometrium and Lipid Levels. Genant et al. (for the Estratab/Osteoporosis Study Group)., Archives of Internal Medicine, 157, Vol 157., Dec 8/22, 1997.
  8. International Clinical Experience with a New Low Dose Monophasic Oral Contraceptive Containing Levonorgestrel 100 ug and Ethinyl Estradiol 20 ug, Boerrigter et al (for the US Levlite Study Group), Clin Therapeautice, Vol 21, No. 1, Jan 1999.
  9. Treatment of Osteoporosis in Postmenopausal Women: Alendronate vs. Intranasal Calcitonin; ACR Annual Meeting, Nov 1999
  10. Effect on Biochemical Markers of Bone Turnover: Alendronate vs. Nasal Calcitonin; ACR Annual Meeting, Nov, 1999
  11. Initial Dose of 17Beta-Estradiol For Treatment of Vasomotor Symptoms, Notelovitz, Lenihan et al., OB-GYN, Vol 95, No.5, May 2000.
  12. Uterine Bleeding in Postmenopausal Women on Continuous Therapy With Estradiol and Norethindrone Acetate., Archer et. al., OB-GYN, Vol. 94, No 3, page 323, Sep. 1999
  13. Transdermal Contraception: An International Study on the Efficacy and Safety of a Contraceptive Patch Smallwood, Meador, Lenihan, Creasy et al: OB-GYN, 98, No5, Part 1, p 799-805., Nov 2001
  14. Postmenopausal Uterine Bleeding Profiles with two forms of Continuous Combined Hormone replacement Therapy (Activella vs. Prem-pro), Johnson Archer, et al (for the Activella Study Group)., Menopause, Vol 9, No 1, page 16-22, Jan 2002

Areas of special interest/expertise

  1. Diagnosis and treatment of Female Pelvic Disorders including use of ultrasound, hysteroscopy, and newer medical and minimally invasive therapies for Pelvic relaxation and Incontinence.
  2. New-Technology (Minimmally-invasive) Surgery (Hysteroscopy, Laparoscopy, Lasers, harmonic scalpels)
  3. Hormone Therapy and Treatment of Menopause
  4. New Contraceptive Technology
  5. Medical Education (Conference organizer, presenter) Course Coordinator of  Annual Current Concepts inPerinatology @ Multi-Care Medical Center 1989 - 1998
  6. Course Coordinator of Semi-Annual Women’s health Care Conference sponsored by Pierce County Medical Society College of Medical Education 1986 – present (Annually)
  7. Adjunct Faculty, MultiCare EndoSurgery Institute: Course faculty at Advance Operative Laparoscopy Courses: 11/93, 4/94, 10/94, 12/94, 11/96, 4/97, 5/98, 11/98, 10/99, 10/00, 4/01

Study experience (Principal Investigator)

  1. Study of Long Term Efficacy and Safety of Combined Contraceptive Vaginal Ring in Healthy Female Volunteers (Organon Inc., 1992)
  2. Safety and Efficacy Comparison of New Oral Contraceptive EE+Desogestrel vs. ON 777 (R.W. Johnson - Ortho, 1992)
  3. Safety and Efficacy of Estrogen XXXX on Bone Mineral Density and Bone Metabolism in Post Menopausal Women (Solvay Pharmaceuticals, 1992 - present)
  4. Safety and Efficacy Comparison of XXXX Vaginal Cream to Monistat Vaginal Cream in the Treatment of Vulvovaginal Candidiasis (Ortho Pharmaceuticals, 1993-1994)
  5. Evaluation of the Efficacy and Safety of Estrogen XXXX on relief of vasomator and Other Symptoms of Menopause (Novo-Nordisk, 1993-1994)
  6. Evaluation of Efficacy and Safety of Combination Estradiol + NETA Transdermal Hormone Patch on Menopausal Symptoms (Thera-Tech 1994-1996)
  7. Safety and Efficacy Study of Desogestrel Containing Oral Contraceptive. (Pharmaco:LSR, Organon Pharmaceuticals Inc. 1993-1994) CTR-25
  8. Safety and Efficacy Study (Open-Label, Randomized, parallel Group) Comparative Multicenter of Tri-Phasic Oral Contraceptive XXXX and XXXX vs. XXXX. (Pharmaco:LSR, Organon Pharmaceutical Inc. 1994-1995)(CTR 77 & CTR 99)
  9. Study of Safety and Efficacy of Hormone Replacement Therapy dosing study of XXXX in three doses vs. XXXX (No Placebo) (Novo-Nordisk Inc., 1994 - 1995)
  10. MultiCenter Double-Blinded Randomized, Placebo-Controlled Efficacy and Safety Study to evaluate Four Doses of Estradiol Given by Continuous Transdermal Administration for the prevention of Osteoporosis in Postmenopausal Hysterectomized Women. (Berlex labs. 1995-1996)
  11. Progestin Efficacy Study of Three doses of Estradiol/Norethisterone Acetate (NETA) Transdermal Patches in a Continuous Wear HRT Regimen compared to an Estradiol 50 Patch. (Rhone-Poulenc Rorer Pharmaceuticals, 1995-1996)
  12. Dose and Endometrial Safety Study of Cyclophasic Hormone Replacement Therapy Regimen of Estradiol and Norgestimate in Postmenopausal Women. R.W. Johnson Pharmaceutical Research Institute, Johnson & Johnson, 1995-1996)
  13. Comparison of Raloxifene HCL, Estrogen, and Placebo on the Uterus in Healthy Postmenopausal Women. (Eli Lilly & Co., 1995-1996)
  14. Safety and Efficacy of Transdermal 17-beta Estradiol System in Treatment of Menopausal Vasomotor Symptoms. (Fournier S.C.A. "Kendle", 1995-1996.)
  15. Open Label Multicenter Study of Safety and Efficacy of Monophasic oral contraspetive containing low dose Levo-Norgestrel (100 ug) and low dose Ethinyl Estradiol (20 ug). (Berlex Laboratories Inc., 1996)
  16.  Triple Blinded Randomized Placebo Controlled Multicenter Study to Evaluater the Efficacy and Tolerability of the Addition of Alendronate Sodium (Fosamax) to ongoing Hormone Replacement Therapy in the Treatment of Osteoporosis in Menopausal Women. (Merk& Co., Inc., 1996 - 1998)
  17. Study to Assess the Safety and Effectiveness of Progestasert@ (Progesterone Releasing Intrauterine System for Menopause - PRISM) for Endometrial Protection in Postmenopausal Women Given Oral Conjugated Estrogen Replacement Therapy. (Alza Pharmaceuticals Inc: 1996 - 1997)
  18. Safety and Efficacy Comparing Three Dosage Combinations of Norethinodrone Acetate plus Ethinyl Estradiol for the Treatment of Vasomotor Symptoms of Menopause (Hot Flash Frequency and Intensity) (MultiCenter, Double Blind, Placebo Controlled.) (Parke Davis Pharmaceuticals, Inc., 1996)
  19. Multicenter Evaluation of Diatomic Iodine-Amylose Complex (DIAC) Capsules for the Treatment of Fibrocystic Disorder of the Breast. (Mimetix, Inc. 1996-97)
  20. Multicenter open-label randomized comparative study to Evaluate the Effects on Cycle Control of Levonorgestrel/Ethinyl Estradiol 100/20 mcg Oral Contraceptive (Wyeth-Ayerst Research 1996-97)
  21. Randomized Double Blind Activer Controlled Parallel-Group Multicenter Study to Assess Menstrual Cycel Control and Ovulation Suppression associated with Vaginal Administration of 5 dose-Combinations of Norethinrone Acetate and Ethinyl Estradiol (in a Vaginal Ring). (Parke Davis Pharmaceuticals, 1997)
  22. Randomized Multicenter Double Blinded study of Cycle Control Efficacy in a Low Dose Oral Contraceptive containing Norgestimate and Ethinyl Estradiol administered in a Cyclo-Phasic Dosing Regimen. (R.W. Johnson - Ortho 1997)
  23. Randomized Multicenter Double Blinded Study to Assess Safety and Efficacy of Combination Estradiol/NETA Transdermal Patch for the Relief of Menopausal Symptoms and Reduction of Endometrial Hyperplasia. (RPR, July 1997)
  24. Randomized Multicenter Double Blinded Study to Assess Safety and Efficacy of Estradiol 7 Day Transdermal Patch in 3 doses to Premarin 0.625 mg/day for the Relief of Menopausal Symptoms. (Ethical Pharmaceuticals, GB 1977)
  25. Triple Blinded, Randomized Multicenter Study Comparing the Efficacy of Oral Alendronate Sodium to Intranasal Calcitonin-Salmon for the Treatment of Postmenopausal Osteoporosis. (Merck & Co., 1997)
  26. Randomized Open Label Study of Contraceptive Efficacy and Safety of a Combination Low Dose Ethinyl Estradiol / Norgestimate Transdermal Contaceptive Patch. (R.W. Johnson 1997)
  27. Randomized Multicenter Open Label Study Evaluating Contraceptive Effectiveness and Safety of Vaginal Contraceptive Ring Containing Ethinyl Estradiol and Norethinodrone Acetate. (Organon 1997-98)
  28. Bleeding Profile with Continuous-Combined Hormone Replacement Therapy: A Randomized Double-Blind Multicenter Comparative Trial of Oral 1 mg 17B-estradiol in combination with 0.25 mg. or 0.5 mg. of Norethidrone Acetate vs. Prempro @. (Novo-Nordisk 1998)
  29. Double Blinded Randomized Placebo Controlled Study to Evaluate the Safety of Tibolone (ORG-OD14) in the treatment of Moderate to Severe Vasomotor Symptoms and Atrophic Conditions Associated with Menopause. (Organon - 1998)
  30. Evaluation of Duloxetine Hydrochloride vs. Placebo in the Relief of Genuine Urinary Stress Incontinence. (Lilly-1998)
  31. Multicenter, Double-blind, Randomized, Placebo Controlled Group Study to determine the Efficacy of a Monophasic Oral Contraceptive (EE-30 mg + Drospirenone 3 mg) in the Treatment of PMS. (Berlex - 1998-99)
  32. Evaluation of Xenical plus Diet in the Treatment of Obesity in Peri/post Menopausal Women with Additional Cardiovascular Risk Factors. (Roche - 1999)
  33. Multicenter Efficacy Study Comparing a Once a Week transdermal preparation of Estradiol and levonorgestrel vs. placebo on the treatment of Severe Vasomotor Symptoms in Menopausal Women. (Solvay 2000)
  34. Randomized Double Blinded Placebo Controlled Parallel Group Study to Evaluate the Safety and Efficacy of a Novel Progesterone Receptor Modulator (PRM – J867) in patients with Symptomatic pelvic Endometriosis (Tap – 2000)
  35. Randomized Double Blinded Placebo Controlled Parallel Group Study to Evaluate the Safety and Efficacy of a Novel Progesterone Receptor Modulator (PRM – J867) in patients with Uterine Fibroids (Tap – 2000)
  36. Randomized Double Blinded Placebo Controlled Parallel Group Study to Evaluate the Safety and Efficacy of an Oral Contraceptive containing Ethinyl Estradiol and a Gestodene in the Management of Severe Premenstrual Syndrome (Berlex – 1999)
  37. Study to Evaluate and validate the “Calendar of Premenstrual Experiences” (COPE) (Berlex 1999)
  38. Randomized Double Blinded Dose Ranging Study to Compare the Safety and Efficacy of a Synthetic 10-Compound Conjugated Estrogen (3 Doses) vs. placebo in Women Suffering From Severe Vasomotor Symptoms. (Endeavor Pharmaceuticals - 2000)
  39. Randomized Double Blinded Placebo Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Six months Therapy with D-chiro-inositol (INS-1) on Ovulatory, Endocrine and Metabolic Abnormalities of Women with Poly-cystic Ovary Syndrome (PCOS) (Insmed – 2000)
  40. Randomized Double Blinded Placebo Controlled Parallel Group Study to Evaluate the Safety and Efficacy of Six months Therapy with D-chiro-inositol (INS-1) on Clomiphene Citrate induced Ovulation in Women with Poly-cystic Ovary Syndrome (PCOS) (Insmed – 2000)
  41. Randomized Double Blinded Placebo Controlled Parallel Group Study to Evaluate the Safety and Efficacy of an Oral Contraceptive Preparation Drospirenone 3 mcg Plus Ethinyl Estradiol 20 mcg in the Management of Severe Premenstrual Dysphoric Disorder (PMDD) (Berlex – 2001)

Disclosure for public speaking and publications

Consultant for

  • Merck & Co.,Inc.
  • Eli Lilly & Co.

Speakers Bureau affilliations with Pharmaceutical Companies:

  • Wyeth Ayerst 1997 - present
  • Park Davis 1993 - present
  • Merck 1996 - present
  • Lilly 1998 - present
  • Rhone-Poulenec-Rourer 1998
  • Ortho-McNeil 2000 - present

Research affilliations with Pharmaceutical Companies:

  • Alza
  • Berlex
  • Fournier
  • Lilly
  • Merck
  • Mimetex
  • Novo-Nordisk
  • Organon
  • Park Davis
  • Rhone-Poulenc Rorer
  • R.W. Johnson (Ortho-McNeil)
  • Thera-Tech
  • Wyeth-Ayerst
  • Solvay
  • Tap
  • Pfizer
  • Watson

Stockholder or Major shareholder: None